Semaglutide — known by brand names Ozempic and Wegovy — works in the brain to impact satiety. Over the past two years, the popularity of weekly injections for weight loss has soared. As of 2024, one in eight adults in the United States has taken a GLP-1 medication (glucagon-like peptide-1 receptor agonists) like Ozempic.

Researchers say semaglutide, the medication in Ozempic and Wegovy, may help reverse MASH, a progressive liver condition affecting millions of Americans.